Tag: HFX
Nevro announces launch of “only AI-driven technology in spinal cord stimulation”
Nevro Corporation has announced the US Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI—a responsive, personalised...
Nevro announces full US market launch of HFX iQ spinal cord...
Nevro Corporation announced today that it has now initiated the full US market launch of its HFX iQ spinal cord stimulation (SCS) system, following...
Nevro announces first global manufacturing operation with Costa Rica expansion
Nevro Corporation announced recently that the US Food and Drug Administration (FDA) has approved its manufacturing operations in Costa Rica for the production of its proprietary...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
